Global Burden Of Disease : Cervical Cancer

Throughout the world, HPV is also very prevalent. Cervical cancer from HPV is the second most common cancer in women living in underdeveloped countries (WHO, 2016). Many of these underdeveloped and lower income countries do have access now to the common forms of the HPV vaccine. In 2008, more than 500,000 new cases of HPV were reported worldwide (WHO, 2016). The prevalence of cases throughout the world is about 79 million reported cases (WHO, 2016).

Cervical cancer is when there are malignant cells present in the cervix; it is developed in the lining of the cervix. A cervix is a narrow opening located at the bottom of the uterus that leads into the vagina. Cervical cancer mostly affects women between the ages of 40 and 55. This cancer can be prevented by screening for precancerous cells, and it can also be cured if it is detected at an early stage. Over the past few decades the number of cervical cancer cases has declined dramatically due to a more widespread screening of the disease. Today, it is estimated that 10,000 new

Cervical Cancer Early Detection Program Journal of Women’s Health 20(10):1479-84 doi: 10.1089/jwh.2010.2530. Epub 2011 Jul 20

Prophylactic vaccination against high risk human papilloma virus 16 and 18 represents an exciting means of protection against HPV related malignancy. However, this strategy alone, even if there is a level of cross protection against other oncogenic viruses, cannot completely prevent cervical cancer. In some countries cervical screening programs have reduced the incidence of invasive cervical cancer by up to 80 percent although this decline has now reached a plateau with current cancers occurring in patients who have failed to attend for screening or where the sensitivity of the tests have proved inadequate. Cervical screening is inevitably associated with significant anxiety for the many women who require investigation and treatment following abnormal cervical cytology. However, it is vitally important to stress the need for continued cervical screening to complement vaccination in order to optimize prevention in vaccines and prevent cervical cancer in older women where the value of vaccination is currently unclear. It is likely that vaccination will ultimately change the natural history of HPV disease by reducing the influence of the highly oncogenic types HPV 16 and 18. In the long term this is likely to lead to an increase in recommended screening intervals. HPV vaccination may also reduce

Almost all cervical carcinomas are caused by Human papillomavirus (HPV). Cervical cancer can be a life-threating disease. However, over recent years the occurrence of cervical cancer has declined as well as the chance of dying from it. A huge contributing factor to this decline is the importance of a regular pap smear. A pap smear can find cervical pre-cancer before it turns into cancer. Recently, a vaccine for HPV, has been on the market, which provides close to a 100% protection against pre-cancer and general warts. HPV and cervical cancer are two disease that are closely related. However, each disease effects not only similar populations, but also different populations, as well as having its own signs and symptoms, detection procedures,

Primarily, cancer of the cervix uteri is affecting women in developing countries such as “sub-Saharan Africa, Melanesia, Latin America and the Caribbean, South-Central Asia, and South East Asia” (Parkin and Maxwell, 2006, p. 1). Given the incidence rates of the different ethnicities aforementioned by the USCSWG, there is no plausible evidence that negates a positive correlation of cervical cancer among racial ethnicities of divergent countries to the United States. To exemplify, Parkin and Maxwell (2006) suggest that the standard age incidence rate (ASR) for cervical cancer in the Caribbean is 33.5 per 100,000, the ASR for sub-Saharan Africa is 31.0 per 100,000, and the ASR for the United States is less than 15.0 per 100,000. Hariri, Unger, Sternberg, Dunne, Swan, Patel, and Markowitz (2011) remark that the prevalence of HPV in Africa-American women was high, even with just having one lifetime partner.

Cervical Cancer affects around 34000 women every year around the UK (Bupa UK, 2013). Cervical Cancer is a result of the mutation of the DNA caused by the by the Human papillomavirus (HPV), (NHS, 2013).

Cervical cancer is a type of abnormal and malignant cell growth on the cervix (birth canal), which causes the common death for American Women. Infected by Human Papillomavirus (HPV) through sexual contact is the main contributor to cervical cancer. According to American Cancer Society’s (ACS) (2017) estimation, around 12,820 people will newly have cervical cancer and about 4,210 people will die from that in 2017. Therefore, it is urgent to decrease the rate of cervical cancer at women. A three-shot Gardasil series vaccine approved by the FDA for girls started to prevent cervical cancer in 2006. There are more than forty types of HPVs and the majority

In US cervical cancer is ranked 13th most common cancer in women and 4th among women between 15 to 44 years.

Vanslyke, J. G., Baum, J., Plaza, V., Otero, M., Wheeler, C., & Helitzer, D. (2008). HPV and Cervical Cancer Testing an

Cervical cancer is formed in the tissues of the cervix, an organ that connects the uterus and the vagina. Virtually all cervical cancers are caused by Human papillomavirus (HPV) infections (Schiffman et. al., 2007). HPV is the most common sexually transmitted infection in the United States. According to the CDC, 75% of sexually active people aged 15-49 have the infection at some point in their lives. (CDC). Because HPV infection is usually asymptomatic, infected people do not know exactly when they get the infection. In most cases, the body is able to fight off the virus before any symptom. However, health problems such as genital warts and cancer may

Cervical cancer is one of the highly popular disease for the women. Different programmes has been made up to fight against this deadly disease. New Zealand has one of the best screening programmes in the world. The establishment of National Cervical Cancer Screening Programme in NZ in 1990 had reduced a significant number of 60% of women who develop cervical cancer and who die from it since it was built. More than 1 million New Zealander women are enrolled in this programme and 95 % are eligible. The Cervical Cancer screening programme aims to; informing women about the importance of having the cervical screening tests; promoting cervical screening tests on a regular basis to women aged 20–70; ensuring high-quality and culturally appropriate services; supporting women with abnormal tests; ensuring there is regular monitoring to see that the goals of the programme are being met. The NCSP also acknowledges the importance of the Treaty of Waitangi in providing a screening programme that is successful for all New Zealand women.

As many as 1,400 women in Canada are diagnosed with cancer of the cervix each year. More than 400 die from it (Mah et al, 2011).

In the United States, it is one of the eight-most common cancer of women. According to researches, the data shows that Hispanic women are significantly more likely to be diagnosed with cervical cancer than the general population and their median age at diagnosis is 48. In 1998, about 12,800 women were diagnosed in the US and about 4,800 died. Among cancers of the female reproductive tract, it is less common than endometrial cancer and ovarian cancer. The rates of new cases in the United States was 7 per 100,000 women in 2004. Cervical cancer deaths decreased by approximately 74% in the

Cervical cancer is one of the leading causes of cancer related mortality in countries such as India accounting for more than 17% of all cancer deaths in women aged 30-69. [3] Cervical cancer is one such type of cancer in which screening plays a significant role. Clinical trials done in below poverty level populations do encounter ethical issues to a certain extent with regards to informed consent as most or all of these patients are illiterate. However informed consent is extremely important when justifying data for such clinical trials. Countries such as US have implemented Pap smear screening as one of the most important cervical cancer screening methods. In countries as densely populated as India where proper healthcare facilities does not reach slums and extremely poverty stricken societies, alternatives for screening are indicated- VIA or Visual inspection with acetic acid